BACKGROUND: Many cancer survivors experience fatigue as a nagging symptom lasting years after treatment. To learn of the relevant biological pathways involved in fatigue among cancer survivors, the authors tested for an association between fatigue levels and leukocyte gene expression profiles and determined the specific mediating immune cell types. METHODS: A sample of 89 Hispanic/ Latino adults aged 60.5 years, 62% of whom were male, who were diagnosed with colorectal cancer and were 2.9 years since diagnosis provided blood for transcriptome profiling and completed a validated measure of fatigue (Multidimensional Fatigue Symptom Inventory-Short Form). The authors applied genome-wide transcriptional profiling of leukocyte RNA to identify gene expression activity associated with fatigue, tested for the activity of specific transcription factors involved in previously established markers of inflammation and immunologic activation, and identified the specific cell types mediating these transcriptional alterations. RESULTS: In analyses adjusting for demographic and behavioral health risk factors, results linked fatigue with increased activation of B lymphocytes and CD8-positive T cells, as well as several transcription factors involved in immune activation (nuclear factor jB [NF-jB], signal transducer and activator of transcription [STAT], and cAMP responsive element-binding protein [CREB]). Results also replicated several specific genomic effects previously observed in fatigued cancer survivors, including upregulated expression of a-synuclein (SNCA) and hemoglobin subunits (HBA and HBB). CONCLUSIONS: Cancer survivors' heightened fatigue levels may be partially explained by activation of specific immune cell subsets, thereby providing a potential molecular biomarker for clinical interventions targeting the remediation of fatigue. Cancer 2018;124:2637-44.
INTRODUCTION
Many cancer survivors experience fatigue as a nagging symptom lasting years after treatment. Fatigue is experienced as physical and/or mental tiredness to exhaustion that is disproportional to the level of exertion. 1 Cancer survivors report fatigue as the symptom that is most disruptive to daily life. 2 The national prevalence of fatigue is approximately 37% for survivors, 3 and >30% can experience fatigue up to 10 years after diagnosis. 4 Proposed culprits include immune and neuroendocrine perturbations from radiotherapy, chemotherapy, treatment with biological agents, and the tumor environment itself. Although our understanding of fatigue is limited, some promising biological mechanisms have been identified, including alteration of immune system activity. 5, 6 Immune cell signaling across inflammatory pathways offers initial insight regarding biological mechanisms of fatigue. Fatigued survivors, either proximal or distal to their treatment period, demonstrate elevated concentrations of proinflammatory markers in peripheral blood compared with those not fatigued. Markers have included interleukin 1 (IL-1), tumor necrosis factor-a (TNF-a), and C-reactive protein. 7, 8 However, some studies do not replicate all signals, 9 and mixed findings arise for other inflammatory markers such as IL-1b and IL-6.
5,10
Studies investigating gene expression in immune cells (leukocytes) also have provided insight into the deeper molecular drivers of fatigue. For example, fatigued survivors of breast cancer demonstrate increased expression of genes bearing response elements for the proinflammatory transcription factor nuclear factor-jB (NF-jB) compared with those not fatigued. 11 Studies also have identified specific individual target genes that are associated with fatigue in patients with cancer, mainly in those exposed to radiotherapy. These include the upregulation of genes coding for a-synuclein (SNCA) and hemoglobin subunits (HB family genes). 12, 13 B and T lymphocytes have been implicated as cellular mediators of these dynamics. [13] [14] [15] However, to the best of our knowledge, the majority of these findings remain provisional because they have not been replicated in independent samples or in different types of cancer. Moreover, it remains unclear how these molecular correlates relate to one another (ie, are they different manifestations of a single common underlying syndrome or do they reflect multiple distinct risk factors that each are sufficient to induce fatigue?).
To test the generality of previously observed molecular correlates of fatigue, we examined the gene expression profile of fatigue in survivors of colorectal cancer. Cancer survivorship is defined herein as the period from cancer treatment onward. We applied genome-wide transcriptional profiling of leukocyte RNA to identify gene transcriptional correlates of fatigue (controlling for relevant demographic and behavioral covariates). We used those transcriptome data as inputs into bioinformatic analyses of transcription factors involved in inflammation and immunologic activation and tested for specific cell types mediating the transcriptional alterations. Guided by findings from previous studies among cancer survivors, we hypothesized that fatigue would map on to a gene expression profile indicative of greater inflammation (eg, NFjB activity), greater activation of stress-related neuroendocrine pathways (eg, cAMP responsive element-binding protein 1/activating transcription factor 1 [CREB/ATF] factors mediating beta-adrenergic influences from the sympathetic nervous system, and glucocorticoid receptors mediating influences from the hypothalamic-pituitaryadrenal axis), and reduced activity of type I interferon antiviral activity (eg, interferon regulatory factor [IRF] factors).
MATERIALS AND METHODS

Participants and Procedure
A subset of participants from the Hispanic Colorectal Cancer Study (HCCS) provided a blood sample and completed additional self-report measures for this study from 2015 through 2016. The HCCS is a population-based cohort study of individuals self-identified as Hispanic or Latino with a confirmed diagnosis of colorectal cancer (CRC) at any stage. 16 All men and women aged >21 years with a first-time diagnosis of CRC (International Classification of Diseases for Oncology, 3rd Edition [ICD- O-3] codes C18-C20) who were able to communicate in English or Spanish were eligible for participation. Cases were identified from the California Cancer Registry and/ or directly from 2 hospitals in Los Angeles (the LAC1USC Medical Center and USC Norris Comprehensive Cancer Center). HCCS participants completed risk factor questionnaires, but only those participants who agreed to provide an additional blood sample, which was optional, were eligible to participate in the current study. The University of Southern California institutional review board approved the current study, and all procedures contributing to this work complied with the ethical standards of the relevant national and institutional committees on human experimentation and with the Declaration of Helsinki.
Assessments
Fatigue
Fatigue was assessed using the 6-item Multidimensional Fatigue Symptom Inventory-Short Form (MFSI-SF) General Fatigue scale. 17 The MFSI-SF is a self-report measure of multiple dimensions of fatigue developed for use with cancer survivors. 18 Response options range from 1 (not at all) to 5 (extremely), with higher scores coded to indicate a greater level of fatigue. Example items used in the current study included "I am worn out," "I feel fatigued," and "I feel run down." In the current study, the scale's Cronbach a was .94. The abbreviated scale was used to reduce respondent burden because participants were completing lengthy questionnaires for the HCCS study. Gene expression analyses used z score standardized scores on the fatigue scale to provide a metric for the identification of differentially expressed genes comparable to that used in previous research (ie, 1.5-fold difference in average RNA expression over the 4-standard deviation [SD] range of normal variation in scale scores). 19 Demographic, biometric, and behavioral covariates
We extracted birthdate and sex from the questionnaires administered to patients and calculated age coincident with the date of blood collection. Socioeconomic assessments included highest educational level and annual household income. Body mass index (BMI) was calculated from self-reported height and weight (kg/m 2 ). A dummy variable for smoking history was coded as 1 if participants reported ever smoking regularly. A dummy variable for alcohol history was coded as 1 if participants reported alcohol use during the last decade of the assessment period.
Original Article
A phlebotomist administered venipuncture to draw a fasting blood sample from participants into vacutainer tubes. Samples were centrifuged at 4 8C at approximately 1300 g for 20 minutes. Buffy coat was extracted and then stored at -80 8C. Samples subsequently were shipped in batches to the University of California at Los Angeles (UCLA) Social Genomics Core Laboratory. RNA was extracted (RNEasy kit; Qiagen, Hilden, Germany), tested for suitable mass (Nanodrop ND1000; Nanodrop Technologies, Wilmington, Delaware) and integrity (Agilent TapeStation System; Aligent, Santa Clara, California), converted to fluorescent cRNA (Illumina TotalPrep RNA Amplification Kit; Ambion, Thermo Fisher Scientific Inc, Waltham, Massachusetts), and hybridized to Illumina Human HT-12 v4 BeadArrays (Illumina Inc, San Diego, California) following the manufacturer's standard protocol in the UCLA Neuroscience Genomics Core Laboratory. All samples were assayed in a single batch, and 88 of the 89 assayed samples yielded valid results according to quality assurance metrics (eg, median probe fluorescence intensity >80 U).
Reference Cell Transcriptome Profiling
To facilitate the identification of the specific leukocyte subtype(s) giving rise to fatigue-related transcriptome alterations, we isolated sets of major leukocyte subpopulations from anonymous donor peripheral blood mononuclear cell (PBMC) samples and conducted genome-wide transcriptional profiling to identify subtype-specific gene transcripts that could provide reference profiles for transcript origin analyses. 20 Given previous data linking fatigue to proinflammatory signaling processes in myeloid-lineage immune cells, 11 the cell isolation protocol specifically differentiated among subpopulations of monocytes and 3 distinct dendritic cell (DC) phenotypes: CD1c-positive (BDCA1-positive) myeloid DCs (DC1), CD303-positive (BDCA2-positive) plasmacytoid DCs (DC2), and CD141-positive (BDCA3-positive) myeloid DCs (DC3). 21 Isolations were conducted using a FACS Aria III (BD Immunocytometry, BD Biosciences, Franklin Lakes, New Jersey) flow cytometer to separate 650 3 10 6 PBMCs into discrete populations of B lymphocytes (CD19 positive), CD4-positive T lymphocytes (CD3 positive/CD4 positive), CD8-positive T lymphocytes (CD3 positive/CD8 positive), natural killer (NK) cells (CD3 negative/CD14 negative/CD56 positive), monocytes (CD14 positive), DC1 (BDCA1 positive/ CD19 negative), DC2 (BDCA2 positive), and DC3 (BDCA3 positive/CD14 negative). 21 B, T, and NK cells were isolated from total PBMCs. Monocytes and DCs were isolated from PBMCs that had been predepleted of CD3-positive and CD19-positive cells by immunomagnetic positive selection (MACS microbeads; Miltenyi Biotech, Bergisch Gladbach, Germany) to enhance flow cytometry-positive event rates (ie, reduce the length of time required to accrue a viable number of DCs, which generally have a prevalence <1% of total PBMCs). All flow sorting was conducted in the UCLA Janis V. Giorgi Flow Cytometry Core Facility and yielded cell populations that were >99% pure. Sorts were conducted on 4 independent PBMC samples (each isolated from Red Cross Leukopak buffy coat specimens by standard ficoll density gradient centrifugation), with 2 samples pooled to create 2 biological replicate samples of each cell type for subsequent transcriptome profiling. Transcriptome profiling was conducted in a single batch as described above using Illumina Human HT-12 v4 BeadArrays. All samples yielded valid data, and these data are publicly available as Gene Expression Omnibus GSE101489.
Statistical Analyses
Gene expression values were quantile-normalized 22 and then log2 transformed for analysis using standard linear statistical models to estimate the association between transcript abundance and (z score-transformed) MFSI-SF scores while controlling for age, sex, BMI, history of smoking (1 or 0), and history of alcohol consumption (1 or 0). Differentially expressed genes were identified as those demonstrating a 1.5-fold difference in expression over the 4-SD range of normal variation in MFSI-SF scores.
A 2-sample variant of the Transcription Element Listening System (TELiS 23 ) was applied to the sets of upregulated and downregulated genes to test whether the observed differences in gene expression could be driven by specific a priori hypothesized transcription factors involved in inflammation and immunologic activation (NF-jB, activator protein 1 [AP-1], CREB/ATF, glucocorticoid receptor [GR] , IRF, and signal transducer and activator of transcription [STAT] ). These analyses tested the (log) ratio of transcription factor-binding motif (TFBM) prevalence for each factor in upregulated versus downregulated promoters, pooled across 9 alternative technical specifications involving parametric variations of promoter length (2300 base pairs [bp] , 2600 bp, and 21000 to 1 200 bp compared with the transcription start site) and TFBM detection stringency (MatSim 0.80, 0.90, and 0.95). 23 To identify specific cell types that contributed to the empirically observed differences in gene expression, we applied transcript origin analysis (TOA) 20 to separate lists of upregulated and downregulated genes. TOA tested for significant overrepresentation of genes preponderantly expressed by a specific subset of PBMCs (ie, monocytes, DCs, CD4-positive T cells, CD8-positive T cells, B cells, or NK cells) using cell-specific reference transcriptomes derived by flow cytometric isolation as described above. We also tested whether MFSI-SF scores were associated with the average expression of 19 gene transcripts previously used as a generalized index of proinflammatory gene expression (IL-1A, IL-1B 19 In all analyses, standard errors for observed bioinformatic statistics were derived from 200 cycles of bootstrap resampling of linear model residual vectors, while accounting for potential correlation among residuals across transcripts.
RESULTS
Sample Characteristics
The sample comprised 89 survivors of CRC with an average age of 60.5 years; the majority were male with a moderately overweight BMI, and were 2.9 years from diagnosis ( Table 1) . Greater than one-half of the sample had a history of smoking regularly. Average MFSI-SF scores (mean, 7.4; SD, 6.3) were similar to previous levels found among survivor samples (range, [5] [6] [7] [8] [9] [10] [11] [12] 24 and for population-based norms (mean, 8.4; SD, 3.6), 25 but were lower than samples from patients with advanced stage cancer (range, [13] [14] [15] [16] [17] [18] [19] . 26 Approximately 18% of the current study sample demonstrated MFSI-SF global scores > 12, which is the national norm for chronically unhealthy individuals. 25 
Gene Expression Correlates of Fatigue
Analyses estimating the magnitude of association between leukocyte gene expression and MFSI-SF scores identified 280 gene transcripts demonstrating a 1.5-fold difference in expression over the 4-SD range of normal variation in MFSI-SF scores after controlling for age, sex, BMI, smoking history, and alcohol use (155 of which were upregulated and 120 of which were downregulated). Upregulated genes (see Supporting Table 1 ) included several transcripts associated with fatigue, such as the amyloid subunit SNCA and multiple hemoglobin subunits (HBA1, HBA2, HBB, and HBG2).
12-15 Other upregulated transcripts included indicators of immunologic activation (human leukocyte antigen [HLA]-B, HLA-H, and LTB) and related transcriptional regulators (EGR1, ETS1, ATF4, high mobility group box 1 [HMGB1], HMGB2, JUND, KLF2, and EIF1), as well as several small nucleolar RNAs (small nucleolar RNA, H/ACA box 3B [SNORA45], SNORA63, SNORD3A, SNORD3C, SNORD3D, SNORD13, and SNORD89). Downregulated genes were difficult to characterize due to the preponderance of unannotated/unnamed transcripts (LOC/HS./ORF) but included the lymphocyte differentiation marker LY6E, several keratin-associated proteins and cadherins (KRTAP6-3, KRTAP19-6, KRTAP21-1, KRTAP21-2, and CHD5), and indicators of type I interferon activity (interferon-stimulated gene 15 [ISG15] and IFI6).
To identity the specific cell types mediating fatiguerelated transcriptional alterations within the overall leukocyte pool, we conducted TOA using reference cell transcriptome profiles derived from immunomagnetically isolated leukocyte subsets (CD4-positive T cells; CD8-positive T cells; B cells; NK cells; monocytes; and DC1, DC2, and DC3). Results identified B lymphocytes, CD8-positive T lymphocytes, and, to a lesser extent, CD4-positive T lymphocytes as the primary cellular origins of gene transcripts upregulated in association with MFSI-SF scores (Fig. 1A) . No individual cell type emerged as a preponderant contributor of gene transcripts that were downregulated in fatigue.
To identify specific transcription control pathways that might mediate the observed differences in gene expression, we conducted TELiS analyses comparing the prevalence of TFBMs in the promoters of genes that were upregulated versus downregulated in association with MFSI-SF scores. Results indicated upregulation of NF-jB, CREB/ATF, and STAT family factors, downregulated activity of IRF factors, and no indication of differential activity for AP-1 or GR (Fig. 1B) .
Previous studies have linked cancer-related fatigue with increased proinflammatory signaling, 11 and therefore we also tested whether MFSI-SF scores might be associated with increased expression of a previously defined set of 19 cardinal proinflammatory gene transcripts. The results demonstrated a positive association at the trend level (P 5 .095) (Fig. 1C) . Although not hypothesized a priori, we also tested a previously defined gene set tracking type I interferon antiviral activity and antibody-related transcription (which often is found to track inversely with proinflammatory gene expression 27 , and did not find a significant association with MFSI-SF scores in this sample.
DISCUSSION
Based on the results of the current study, we found that heightened levels of fatigue among survivors of CRC appear to be associated with upregulated activity in the adaptive immune system, including increased activation of B lymphocytes and CD8-positive T lymphocytes, elevated activity of transcription factors involved in lymphocyte activation and inflammation (NF-jB, STAT, and CREB/ATF), and reduced activity of IRFs. At the level of individual gene transcripts, these alterations included upregulation of SNCA and hemoglobin subunits (HBA and HBB), which corroborates results previously observed in patients with cancer-related fatigue. 12, 13 To the best of our knowledge, the current study is the first to replicate previous exploratory findings as a priori hypotheses, the first to document correlates of fatigue in patients with CRC, and the first to extend such results to a Hispanic/ Latino sample, lending to enhanced generalizability of the findings across race/ethnicity. Moreover, the simultaneous documentation of transcriptional alterations at the level of specific individual genes (eg, SNCA, HBA/HBB), upstream transcription factors (eg, NF-jB, STAT, CREB/ATF, and IRF), and their broader cellular context (eg, B lymphocytes, CD8-positive T cells) suggests that each of these processes may reflect different manifestations of a single common underlying syndrome involving dysregulation of the adaptive immune response.
The results of the current study are particularly striking in replicating associations of several specific transcripts with cancer-related fatigue, including the amyloid subcomponent SNCA and several hemoglobin subunits (HBA1, HBA2, HBB, and HBG2). 12, 13, 15 The findings of the current study also converged to some degree with previous observations relating cancer-associated fatigue with the increased activity of proinflammatory signaling pathways (eg, activation of NF-jB, CREB/ATF, and STAT family transcription factors, as well as a trend toward increased activity of the a priori-specified composite of 19 canonical proinflammatory gene transcripts). However, the current study data demonstrated no evidence of altered activity of the anti-inflammatory GR signaling pathway or of the monocyte lineage cell types that mediate classic inflammatory reactions. Instead, the results herein implicated lymphoid lineage cells, particularly B lymphocytes and CD8-positive T lymphocytes. Previous studies also have implicated B cells in the leukocyte transcriptomic correlates of fatigue. 14, 15 Consistent with that observation, SNCA is known to influence B-cell homeostasis and differentiation in addition to its better known role in neuronal integrity as the non-A b component of Alzheimer disease amyloid. 28 Past research assessing inflammatory markers using genome-wide transcription profiling have focused on patients with breast cancer, and these studies have demonstrated variability in methodology, particularly fatigue measures and sampling techniques. 5, 6, 29 The discontinuity of the current study results with the more classic myeloid/inflammatory profile observed in previous studies of posttreatment fatigue in patients with breast cancer 11 may represent distinct pathophysiological pathways in distinct cancer types (ie, CRC in the current study vs breast cancer in the previous study) and/or differences in the time elapsed after radiotherapy and other cancer treatments. In particular, CRC may involve more extensive surgery and more extended exposures to radiation and chemotherapy, and those differences may contribute to differences in the immunoregulatory gene expression profiles observed in the current study compared with previous studies of patients with early-stage breast cancer. In addition, racial and ethnic differences in the experience of cancer survivorship, including higher reported obesity rates (defined by the Centers for Disease Control and Prevention as an adult BMI >30.0), may affect the relevant biological pathways and associated gene expression profiles involved in fatigue among Hispanic/Latino survivors of CRC. 30, 31 More studies regarding racially and ethnically diverse cancer survivors with a variety of cancer diagnoses are needed to elucidate the possible influence of these factors on symptoms after treatment. 31 The results of the current study also differ from previous observations in linking cancer-related fatigue with reductions in type I interferon-related signaling, including downregulation of specific interferon response genes (eg, ISG15, IFI6) as well as reduced activity of IRF transcription factors. However, we observed no significant downregulation of a broader set of 34 prespecified interferonrelated and antibody-related genes, suggesting that the observed downregulation is specific to a narrow range of interferon-related transcripts. The biological significance of this observation remains to be clarified in future research, but it could represent a compensatory side effect of the observed increases in NF-jB signaling activity, because NF-jB is known to reciprocally cross-regulate IRF activity. 32, 33 Alternatively, this observation may reflect a selective deficit in type I interferon containment of a chronic viral infection that subsequently contributes to fatigue (eg, as hypothesized in chronic fatigue syndromes). Future research assessing the role of subclinical viral infections such as Epstein-Barr virus or cytomegalovirus may help to clarify the basis for these observations.
Study Limitations
One limitation of the current study involves the crosssectional study design, which precluded drawing any conclusions regarding the direction of causal relationships among gene expression activity and fatigue. The observed associations may reflect a causal effect of immunologic activation on the central nervous system processes involved in arousal and motivation (eg, as in the "sickness behavior" literature). 4, 34, 35 However, the profile of transcription factor alterations observed herein (elevated proinflammatory and reduced antiviral) is reminiscent of the stress-induced "conserved transcriptional response to adversity" profile, 27 suggesting that at least some of the observed transcriptomic correlates of fatigue could potentially reflect the effects of fatigue-related distress on immune cell gene regulation. Associations also may reflect the effects of stressful life circumstances that causally influence both experienced fatigue and immune cell gene expression. It also is important to note that no assessments of clinical health outcomes or immune function were available in this sample, and therefore the implications of the observed transcriptome differences for health remain to be determined in future studies.
Clinical Implications
The findings of the current study identified a systematic alteration in lymphocyte gene regulation that may serve as a target for future interventions to reduce cancerassociated fatigue. Based on these findings, therapeutic strategies that reduce CD8-positive T-cell and/or B-cell activation should be considered for potential use in cases of severe or persistent cancer-related fatigue (eg, monoclonal antibodies targeting cell type-specific activation receptors). Moreover, the RNA-based measures of CD8-positive T-cell and B-cell activation, activation-related transcription factor activity (eg, NF-jB, STAT, and CREB), and specific replicated transcript alterations (SNCA, HBA, and HBB) identified herein may potentially be used as biomarkers to gauge the impact of pharmacologic or behavioral interventions to reduce fatigue. 36 The establishment of replicated molecular biomarkers thus provides new horizons for the clinical management of cancer-related fatigue. 
